tbuckley/cabot-search huggingface dataset:
Molecular Analysis of Isophthalate and Terephthalate Degradation by Comamonas testosteroni YZW-D
Authors: Yong Zhao Wang, Yiming Zhou, Gerben J. Zylstra
Journal: Environmental Health Perspectives (1995)

Comamonas testosteroni YZW-D was isolated from Passaic River sediment for its ability to degrade isophthalate and terephthalate.Degradation of the two isomeric compounds proceeds via separately inducible catabolic pathways that converge at protocatechuate.Analysis of the catabolic pathways by which these two isomers are degraded demonstrated that a cis-dihydrodiol intermediate is involved in both pathways.The genes for the conversion of isophthalate and terephthalate to protocatechuate were cloned on a single fragment of genomic DNA from C. testosteroni YZW-D.The two operons were located by subcloning and mutant complementation experiments.The regions coding for the two degradative pathways were sequenced.Analysis of the nucleotide sequence for the isophthalate degradation operon located genes for a dioxygenase, a transport protein, a cis-dihydrodiol dehydrogenase, and a reductase.Analysis of the nucleotide sequence for the terephthalate degradation operon located genes for a regulatory protein, a transport protein, a dioxygenase large subunit, a dioxygenase small subunit, a cis-dihydrodiol dehydrogenase, and a reductase.
L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia
Authors: J. M. Hill
Journal: JAMA (1967)

Enzyme therapy directed at depletion of an amino acid, asparagine, indispensable for tumor cell growth but not required by normal tissues, offers a new and promising approach to the problem of treatment of leukemia and disseminated cancer. Therapy with the enzyme L-asparaginase in three cases of acute lymphatic leukemia resulted in measurable improvement in two advanced cases. In the third case, there was a striking response to large dosage, with rapid necrosis of lymph node masses and clearing of leukemic infiltrates. A laboratory test to detect dependency of tumor cells on asparagine seems helpful for selection of cases for investigation of therapy. Furthermore, a variety of human malignant diseases including acute lymphatic leukemia and acute and chronic granulocytic leukemia have been shown to be asparagine-dependent by this test. Exploitation of further possible nutritional differences offers a fertile field for investigation.
Truth or Consequences: What to Do When the Patient Doesn’t Want to Know
Authors: Pamela Neff, Laurie Lyckholm, Thomas Smith
Journal: Journal of Clinical Oncology (2002)

Article Tools THE ART OF ONCOLOGY: WHEN THE TUMOR IS NOT THE TARGET Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.13.3035 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12089236 Truth or Consequences: What to Do When the Patient Doesn’t Want to Know Pamela NeffxPamela NeffSearch for articles by this author , Laurie LyckholmxLaurie LyckholmSearch for articles by this author , Thomas SmithxThomas SmithSearch for articles by this author Show More From the Department of Internal Medicine, Division of Hematology/Oncology, Virginia Commonwealth University School of Medicine, Richmond, VA. https://doi.org/10.1200/JCO.2002.20.13.3035 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
The role of topoisomerase II-α (TOPO IIA) as a predictive factor for response to neoadjuvant anthracycline-based chemotherapy in locally advanced breast cancer
Authors: M.M. Gamea
Journal: Annals of Oncology (2018)

Background: Topoisomerase II-α is a molecular target of anthracyclines; several studies have suggested that topoisomerase II-α expression is related to response to anthracycline treatment. The objective of this study was to evaluate whether topoisomerase II-α overexpression predicts response to anthracycline treatment in locally advanced breast cancer patients. Methods: This prospective study included 50 patients with primary non-metastatic locally advanced breast cancer according to American Joint Committee for Cancer Staging(T3-4;N0-3) treated between January 2012 and Jaune 2012 at Clinical Oncology Department, Tanta University Hospital. Topoisomerase II-α, HER2, estrogen receptor (ER), progesterone receptor (PR) expression and KI-67 were evaluated by immunohistochemistry in formalin-fixed, paraffin-embedded breast tumors from 50 patients presenting with locally advanced breast cancer. Results: Tumors from 50 patients, 45 (90%) showed topoisomerase II-α overexpression, patients 34 (68%) for ER positive, 32 (64%) for PR positive, and 10 (20%) for HER2 overexpression and 16 (32%) for high KI 67. Significant correlation between clinical and pathological response was observed with topo IIA, HER2 and KI-67: p values of ≤0.001, 0.005 and 0.015, respectively. 1. Responders: Clinical CR: 3 patients had co-expression of topo II and HER2, hormonal receptor negative and high KI-67. Clinical PR: 43 patients majority of them had topo IIA overexpression .fig(9-10) 2. Non responders: 4 (8%) patients all had negative (TOPOII/HER2), low KI-67 and 2 were hormone receptor positive, and another 2 were hormone receptor negative. Conclusions: Our data support a correlation between topoisomerase II-α expression in locally advanced breast cancer patients and improved clinical benefit with neoadjuvant anthracycline-based therapy. Funding: Has not received any funding. Disclosure: The author has declared no conflicts of interest.
Abstract 2604: Constitutive activation of the human aryl hydrocarbon receptor in mice promotes hepatocarcinogenesis independent of its coactivator Gadd45b
Authors: Peipei Lu, Xinran Cai, Zihui Fang, Wen Xie
Journal: Cancer Research (2019)

Abstract 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), or dioxin, is a potent liver cancer promoter through its sustained activation of the aryl hydrocarbon receptor (Ahr) in rodents. However, the carcinogenic effect of TCDD and AHR in humans has been controversial. It has been suggested that the inter-species difference in the carcinogenic activity of AhR is largely due to different ligand affinity in that TCDD has a 10-fold lower affinity for the human AHR compared to the mouse Ahr. It remains unclear whether the activation of human AHR is sufficient to promote hepatocellular carcinogenesis. The goal of this study is to clarify whether activation of human AHR can promote hepatocarcinogenesis. Here we reported the oncogenic activity of human AHR in promoting hepatocellular carcinogenesis. Constitutive activation of the human AHR in transgenic mice was as efficient as its mouse counterpart in promoting diethylnitrosamine (DEN)-initiated hepatocellular carcinogenesis. The growth arrest and DNA damage-inducible gene 45 β (Gadd45b), a signaling molecule inducible by external stress and UV irradiation, is highly induced upon AHR activation. Further analysis revealed that Gadd45b is a novel AHR target gene and a transcriptional coactivator of AHR. Interestingly, ablation of Gadd45b in mice did not abolish the tumor promoting effects of the human AHR. Collectively, our findings suggested that constitutive activation of human AHR was sufficient to promote hepatocarcinogenesis. Note: This abstract was not presented at the meeting. Citation Format: Peipei Lu, Xinran Cai, Zihui Fang, Wen Xie. Constitutive activation of the human aryl hydrocarbon receptor in mice promotes hepatocarcinogenesis independent of its coactivator Gadd45b [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2604.
Mannose-Binding Lectin Status Is Associated with Risk of Major Infection Following Myeloablative Sibling Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Charles G. Mullighan, Susan E. Heatley, Silke Danner, Melinda Dean, Kathleen V. Doherty, Uwe Hahn, Kenneth Bradstock, Robyn Minchinton, Anthony P. Schwarer, Jeffrey Szer, Peter G. Bardy
Journal: Blood (2006)
OVARIAN NISUS NOT THE DETERMINING CAUSE OF LABOR.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Two more screens per woman would improve effectiveness of UK breast cancer screening
Journal: BMJ (1998)

Changed criteria for diabetes need further researchIn 1997 the American Diabetes Association changed the diagnostic fasting plasma value for glucose from 7.8 to 7.0 mmol/l.For screening and epidemiological studies they no longer recommended the standard 75 g oral glucose tolerance test recommended by the WHO.The DECODE Study Group's reanalysis of epidemiological studies in eight European countries-more than 26 000 patients-found that the two diagnostic criteria agreed in only 431 of 1517 people classified as diabetic (p 371).Because of this reclassification the group says that the WHO should wait for results of further reanalyses, with focus on prognostic impact, before it considers adopting the ADA criteria.
PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation
Authors: Yi-Bin Chen, Philippe Armand, Robert A. Redd, Jad Bsat, Reid W Merryman, Kimberly Coleman, Alex F. Herrera, Parastoo B. Dahi, Yago Nieto, Ann S. LaCasce, David C. Fisher, Samuel Y. Ng, Oreofe O. Odejide, Arnold S. Freedman, Austin I Kim, Jennifer L Crombie, Caron A. Jacobson, Eric D Jacobsen, Jeffrey L Wong, Sanjay S Patel, Jerome Ritz, Scott J Rodig, Margaret A. Shipp, Robin M. Joyce
Journal: Blood (2018)
Against minimalism in breast cancer follow-up
Authors: M. D. Wertheimer
Journal: JAMA (1991)

BREAST CANCER in 1990 continues to be a problem of major public health proportions. Approximately 10% of women in the United States (150 000) will be newly diagnosed in 1990 as having breast cancer. Breast cancer is the most common cancer in women and still one of the leading causes of death for adult American women. Approximately 44 000 women will die of breast cancer this year alone.<sup>1</sup>This number approaches the total number of American deaths in the Vietnam Conflict. These stark numbers mask a great deal of suffering and misery that statistics do not adequately portray and that neither clinical oncology nor public policy has been able to influence greatly. Effective prevention strategies are lacking, and research in this area is limited. The approach that has been taken to improve these grim statistics includes mammographic screening for early detection of disease, aggressive primary and adjuvant therapy, and
MORTALITY AND CAUSES OF DEATH IN MEDICAL MEN.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SIR DYCE DUCKWORTH ON MEDICAL BULLETINS
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
at a glance..: one-minute abstracts of the current literature on cancer...
Journal: CA A Cancer Journal for Clinicians (1953)

Cytological Screening Procedure for Cancer of the CervixThe cervical smear is much more accurate thanthevaginal smearinre vealing unsuspected or preclinical can cer.In the Cancer Cytology Center at theDade CountyCancerInstitute, the costof finding an unsuspected caseof cancerof thecervix isapproximately $300.Although it may not yet be feasible or financially justifiable to undertake large-scale screening at the State level, steps should be takentoset up cytology centers for active training oftechnicians, pathologists, andcytolo gists.In several centers cervical cyto tests are yielding excellent results as a screening procedure in the family physician's office.The familyphysi cian's office is the logical cancer-detec tion clinic today.
Figures Reversed.
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Subclinical Hyperthyroidism
Authors: David M Williams, Jeffrey W Stephens, David E Price
Journal: New England Journal of Medicine (2018)

venous systems in 46.8% of cases in the EVRA trial. 1 A previous trial showed that foam sclerotherapy for truncal incompetence resulted in a lower occlusion rate (51%) at 1 year than did endovenous laser ablation (97%), with up to 54% of patients requiring additional treatment by 5 years. 4 We propose that if thermal ablation had been used exclusively in the trial by Gohel et al., the healing rates may have been even higher in the intervention groups. 4,5
ADDRESS.
Authors: U. O. B. WINGATE
Journal: JAMA (1895)

It has sometimes seemed to me that an address on occasions like this, smacked somewhat like a dish of dessert at the end of a banquet, when every one had partaken of more than enough. I am sure that the students in the college have had their fill; I can not conceive that the Faculty are hungry for any words from one of their number; and I have grave doubts about any of the friends present being in possession of a keen relish for anything oratorical at this time. However, we seem to be victims of custom's decree, but I promise not to weary you long. The Wisconsin College of Physicians and Surgeons has completed the second year's work of its existence, a work that speaks for itself and needs no encomiums from me. It prides itself on having earnest, faithful and conscientious teachers, students in liberal numbers, zealous in
How States Are Legislating Workforce Planning, Part 2
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Failure of Perchlorate to Inhibit Tc-99m Isonitrile Binding by the Thyroid during Myocardial Perfusion Studies
Authors: A CAHID CIVELEK, KRZYSZTOF DURSKI, IRFAN SHAFIQUE, KANAME MATSUMURA, SAMUEL SOSTRE, HENRY N. WAGNER, PAUL W. LADENSON
Journal: Clinical Nuclear Medicine (1991)

The thyroid gland receives an average radiation dose of 3 rads during two Tc-99m isonitrile (MIBI) myocardial perfusion studies, if 20 mCi is administered both at rest and at peak exercise. In patients with coronary artery disease, multiple myocardial perfusion studies may be required, resulting in a high level of thyroid radiation. We attempted to reduce this radiation exposure by blocking thyroidal Tc-99m MIBI uptake with oral potassium perchlorate (KCIO4). Fourteen normal subjects received 0.6g to 0.8g KCIO4 20-25 minutes before tracer injection. Subjects who received KCIO4 at rest (n=11) did not receive KCIO4 at their stress study, and vice versa (n=3). Thyroid uptake values were obtained with a thyroid probe 20 minutes after injection for both rest and stress studies and were corrected for saturation effects. There was no difference between fractional thyroid uptake values with and without preceding perchlorate administration: 1.9 ± 0.5% and 1.8 ± 0.3% (mean ± SD), respectively. Failure to block Tc-99m MIBI uptake after intravenous (IV) injection is probably due to high thyroidal blood flow and nonspecific tracer accumulation. The concentration of this radioisotope in adjacent muscles also contributes to the high thyroid radiation dose. In summary, administration of KCIO4 before Tc-99m MIBI studies does not reduce the thyroidal radiation dose or uptake of this tracer, suggesting that thyroidal uptake of this tracer is not mediated by the iodine trapping mechanism.
"RECONSTRUCTION AND REHABILITATION OF THE TUBERCULOUS SOLDIER"
Authors: E. H. Bruns
Journal: JAMA (1918)

<h3>To the Editor:</h3> —Dr. Banks' letter (The Journal, Aug. 24, 1918, p. 681) criticizing my paper entitled "The Reconstruction and Rehabilitation of the Tuberculous Soldier" requires some comment. It was not the intention of the writer to belittle in any way the valuable work being done by the Bureau of War Risk Insurance. It is true that discharged tuberculous soldiers are being looked after medically by the Bureau of War Risk Insurance, but my not calling attention to this fact was no greater an oversight than my failure to mention the American Red Cross, National Association for the Study and Prevention of Tuberculosis, the National Home for Disabled Volunteer Soldiers, and the Soldiers' Home, Washington, D. C., which are all doing equally commendable work in this line. However, from Dr. Banks' own statement it would appear that the activities of the Bureau of War Risk Insurance must be largely confined
From the Centers for Disease Control. Coronary heart disease incidence, by sex
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal